Active Pharmaceutical Ingredientia
| Progestogen et Estrogen | |||
| Product Name | Specification | Probatus | CAS Non. |
| Progesterone | CP/EP/USP/JP | CEP/EU-GMP/FDA | 57-83-0 |
| Pregnenolone | In domo |
Kosher | 145-13-1 |
| Medroxyprogesterone Acetate | CP/EP/USP/JP | DMF/GMP | 71-58-9 |
| Megestrol acetate | CP/EP/USP | DMF in processususus | 595-33-5 |
| Mifepristone | CP/IP | DMF/GMP | 84371-65-3 |
| Cyproterone Acetate | CP/EP/IP/KP | CEP/TGA/EU-GMP | 427-51-0 |
| Levonorgestrel | CP/EP/USP/IP | CEP/GMP | 797-63-7 |
| Norethisterone |
CP/EP/USP/JP |
DMF in processususus |
68-22-4 |
| Norethisterone Acetate |
EP/USP |
DMF in processususus |
51-98-9 |
| Norethisterone Enanthate |
In domo |
Sub R&D |
3836-23-5 |
| Drospirenone | EP/USP | DMF | 67392-87-4 |
| Gestodene | CP/EP | DMF/GMP | 60282-87-3 |
| Estradiol | CP/EP/USP/KP | DMF/GMP/WC | 35380-71-3 |
| Estriol | CP/EP/USP | Sub R&D | 50-27- 1 |
| Ethinyl Estradiol | CP/EP/USP | GMP | 57-63-6 |
| Estradiol Valerate | CP/EP/USP/KP | DMF | 979-32-8 |
| Estradiol Cypionatus |
USP | DMF in processususus |
313-06-4 |
| Promestriene |
In domo |
Sub R&D |
39219-28-8 |
| Tibolone | CP/EP | DMF/GMP | 5630-53-5 |
| Dienogest | EP | CEP/GMP | 65928-58-7 |
| Fulvestrant | EP/USP | Sub R&D | 129453-61-8 |
| Exemestane | CP/EP/USP | Sub R&D | 107868-30-4 |
| Androgen | |||
| Product Name | Specification | Probatus | CAS Non. |
| Finasteride | CP/EP/USP | CEP/FDA/PMDA/GMP | 98319-26-7 |
| Dutasteride | EP/USP | CEP/FDA | 164656-23-9 |
| Abiraterone Acetate | CP/USP | DMF/GMP/WC | 154229-18-2 |
| Darolutamide |
In domo |
Sub R&D |
1297538-32-9 |
| Testosterone | CP/EP/USP | CEP/FDA/WC | 58-22-0 |
| Testosterone Undecanoate | CP | DMF/WC | 5949-44-0 |
| Testosterone Cypionate | USP | DMF | 58-20-8 |
| Testosterone Enanthate |
USP/JP | Sub R&D |
315-37-7 |
| Testosterone Propionate |
CP/EP/USP/JP |
Sub R&D |
57-85-2 |
| DHEA | FP/In domo | DMF/WC/Kosher | 53-43-0 |
| Clascoterone | In domo | DMF in processususus | 19608-29-8 |
| Cortical Hormone | |||
| Product Name | Specification | Probatus | CAS Non. |
| Budesonide | CP/EP/USP/JP | CEP/FDA/GMP | 51333-22-3 |
| Desonide | CP/USP | DMF/GMP | 638-94-8 |
| Eplerenone | EP | CEP in processuu | 107724-20-9 |
| Methylprednisolone | CP/EP/USP/JP | DMF/GMP | 83-43-2 |
| Methylprednisolone Hemisuccinate | CP/EP/USP | DMF/GMP | 2921-57-5 |
| Fluticasone Propionate | CP/EP/USP | DMF | 80474- 14-2 |
| Fluticasone Furoate | CP/EP | DMF in processususus | 397864-44-7 |
| Mometasone Furoate |
CP/EP/USP |
DMF in processususus |
Anhydrous (83919-23-7) Monohydratorum (141646-00-6) |
| Deflazacort |
In domo |
Sub R&D |
14484-47-0 |
| alii | |||
| Product Name | Specification | Probatus | CAS Non. |
| Oxcarbazepine | CP/EP/USP/IP | CEP/FDA/GMP | 28721-07-5 |
| Eslicarbazepine Acetate | CP/USP | DMF | 236395- 14-5 |
| Ganciclovir | CP/EP/USP | DMF/GMP | 82410-32-0 |
| Valganciclovir Hydrochloride | USP/EP | CEP in processu | 175865-59-5 |
| Oseltamivir Phosphate | CP/EP/USP | DMF | 204255- 11-8 |
| Baloxavir Marboxil | In domo | Sub R&D | 1985606-14-1 |
| Revefenacin | In domo | DMF | 864750-70-9 |
| Mirabegron | CP/EP | DMF | 223673-61-8 |
| Vibegron |
In domo |
Sub R&D |
1190389-15-1 |
| Escitalopram Oxalate | CP/EP/USP | DMF in processusus | 219861-08-2 |
| Citalopram Hydrobromide |
CP/EP/USP |
DMF in processususus |
59729-32-7 |
| Cariprazine hydrochloride | In domo | DMF | 1083076-69-0 |
| Lasmiditan Succinate | In domo | DMF | 439239-92-6 |
| Iuliconazole | In domo | DMF | 187164-19-8 |
| Nintedanib Esylate |
In domo |
FDA/DMF/WC |
656247-18-6 |
| Apalutami | In domo | DMF | 956104-40-8 |
| Tadalafil | CP/EP/USP | Sub R&D | 171596-29-5 |
| Relugolix | In domo | DMF in processusus | 737789-87-6 |
| Ruxolitinib phosphate |
In domo |
DMF in processususus |
1092939-17-7 |
| Abemaciclib |
In domo |
Sub R&D |
1231929-97-7 |
| Phloroglucinol | CP/EP | DMF | 108-73-6 |
| 1,3,5-Trimethoxybenzene |
CP/In-domus |
GMP |
621-23-8 |
| Acidum Ursodeoxycholic | EP/USP/JP | Sub R&D | 128-13-2 |
| Tauroursodeoxycholic Acid |
In domo |
Sub R&D |
14605-22-2 |
| Cura |
CP/EP/USP/JP |
Sub R&D |
57-88-5 |
| Omega-3-Acid Ethyl Ethers 90 |
EP/USP |
DMF in processususus |
-- |
| Medium-Chain Triglycerides |
CP/USP/EP |
DMF |
-- |
| Benzalkonium Chloride |
USP/EP/JP |
CEP in processuu |
8001-54-5 |
| Oleum olivae (For Iniectio) |
CP/USP/EP/JP |
DMF in processususus |
8001-25-0 |
| Ovum phospholipids (nam Iniectio) |
CP/USP/EP |
DMF |
93685-90-6 |
| PORTIO |
In domo |
DMF in processususus |
203787-91-1 |
Progesterone EP, USP, CP, JP, IP et KP specificationes habet.CEP in promptu sunt, EU-GMP,FDA approbavit.
Finasteride EP, USP, CP, IP, JP in promptu habet, FDA, PMDA et GMP approbavit.
Budesonide habet USP, EP specificationes. CEP, GMP et FDA probatus est.
Dutasteride EP, USP, CP, IP, JP specificationem habet. CEP et FDA praesto.
Desonide USP et EP specificationes habet. DMF praesto.
Methylprednisolone specificationes USP, EP, IP, JP, KP habet. DMF and WC available.